Lurbinectedin Monotherapy in Participants With Advanced or Metastatic Solid Tumors
Public ClinicalTrials.gov record NCT05126433. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
EMERGE-201: A Phase 2, Multicenter, Open-label Study of Lurbinectedin Efficacy and Safety in Participants With Advanced or Metastatic Solid Tumors
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is an open-label, multicenter, phase 2 study of lurbinectedin monotherapy in participants with advanced (metastatic and/or unresectable) solid tumors.
Study identification
- NCT ID
- NCT05126433
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 47 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 3, 2022 (Actual)
- Primary completion
- Dec 20, 2023 (Actual)
- Completion
- Dec 20, 2023 (Actual)
- Last update posted
- Feb 28, 2025
2022 – 2023
United States locations
- U.S. sites
- 17
- U.S. states
- 14
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Stanford Cancer Center | Stanford | California | 94305 | — |
| Eastern Connecticut Hematology and Oncology | Norwich | Connecticut | 06360 | — |
| Florida Cancer Specialists | Fort Myers | Florida | 33901 | — |
| Sarah Cannon, Florida Cancer Specialist | St. Petersburg | Florida | 33705 | — |
| Moffitt Cancer Center | Tampa | Florida | 33612 | — |
| Pikeville Medical Center | Pikeville | Kentucky | 41501 | — |
| Dana Farber | Boston | Massachusetts | 02215 | — |
| Oncology Hematology West, PC dba Nebraska Cancer Specialists | Omaha | Nebraska | 68124 | — |
| Icahn School of Medicine at Mount Sinai | New York | New York | 10029 | — |
| Levine Cancer Institute | Charlotte | North Carolina | 28203 | — |
| Sarah Cannon, Zangmeister Cancer Center | Columbus | Ohio | 43219 | — |
| University of Pennsylvania | Philadelphia | Pennsylvania | 19104 | — |
| UPMC Hillman Cancer Center Investigational Drug Service | Pittsburgh | Pennsylvania | 15232 | — |
| Bon Secours Hematology and Oncology | Greenville | South Carolina | 29607 | — |
| Sarah Cannon, Tennesse Oncology | Nashville | Tennessee | 37203 | — |
| MD Anderson | Houston | Texas | 77030 | — |
| Inova Schar Cancer Institute | Fairfax | Virginia | 22031 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05126433, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 28, 2025 · Synced Oct 31, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05126433 live on ClinicalTrials.gov.